In conclusion, the results of these analyses suggest that PMS, CRP, and corticosteroid use are all characteristics that could be evaluated after 8 weeks of tofacitinib induction therapy to provide some prediction as to whether patients are likely to achieve remission or lose response to tofacitinib maintenance therapy. The gene discussed is CRP; the disease is premenstrual tension.